[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company

December 2016 | 288 pages | ID: A23BD1EA44AEN
La Merie Publishing

US$ 880.00

Online Subscription

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company

The competitive intelligence report „Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company“ evaluates and describes the competitive landscape of antibody-drug conjugates (ADCs) in a tabular format by target, payload, R&D phase and company as of December 2016.

Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Since our last ADC Competitor Analysis in April 2013, the number of ADCs in active clinical development has doubled from 33 in 2013 to 65 at the end of the year 2016. Among them are eight ADCs in late stage development or under regulatory review. More than 20 ADCs are in the IND stage or undergoing IND-enabling studies. This analysis identified further 58 preclinical stage ADC projects and 22 ADC discovery programs. However, the number of ADCs discontinued from clinical development also has increased.

The report furthermore lists the ADCs by target, drug payload, and by company portfolio.

Among the popular targets of ADC developments identified in the search are:
  • Her2
  • CD30
  • CD33
  • CD22
  • CD19
  • PSMA
  • 5T4
  • EGF-R
  • CEACAM5
  • CD37
  • CD38
  • CD25
  • CD70
  • Mesothelin
  • c-Met
  • MUC16
  • CD123
  • Tissue Factor
  • TROP-2
  • FGF-R
  • Ephrin-A
in addition to unique targets identified by companies with proprietary target discovery programs.

With the increasing number of ADCs in development and of companies with in-house ADC technology development, new payloads are being evaluated in early clinical studies.

The report includes a compilation of currently active as well as discontinued ADC R&D. In addition, the report lists company-specific R&D pipelines of ADCs. Competitor projects are listed in a tabular format providing information on:
  • Drug Codes,
  • Target/Mechanism of Action,
  • Class of Compound (antibody, linker, payload),
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments about latest results with a hyperlink leading to the source of information.
About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
1. ANTIBODY-DRUG CONJUGATES (ADCS) BY TARGET

Kadcyla Indication Pipeline
  Her2
Adcetris Indication Pipeline
  CD30
  CD33
  CD22
  CD19
  PSMA
  5T4
  EGF-R
  CEACAM5
  CD37
  CD38
  CD25
  CD70
  Mesothelin
  c-Met
  MUC16
  CD123
  Tissue Factor
  TROP-2
  FGF-R
  Ephrin-A
Unique Targets of ADCs from Big Pharma & Biotech
Unique Targets of ADCs from Mid Size Biotech & Pharma
Unique Targets of ADCs from Small Biotech
Not Disclosed Targets of ADCs from Big Pharma & Biotech
Not Disclosed Targets of ADCs from Small Biotech

2. NON-ONCOLOGY INDICATIONS FOR ADCS

3. DISCONTINUED CLINICAL STAGE ANTIBODY-DRUG CONJUGATES

4. ADCS BY HIGHEST R&D PHASE

Approved and Late Stage Clinical Development
  Early Stage Clinical Development
  IND and Pre-IND Stage Development
  Preclinical Stage Development
  Discovery Stage

5. ADCS BY DRUG PAYLOAD

Monomethyl Auristatin E and F (MMAE / MMAF)
  Other Auristatins
  Pyrrolobenzodiazepine (PBD)
  Other DNA Targeted Agents
  Maytansinoids
  Topoisomerase Inhibitors
  Other Microtubule/Mitosis Targeted Agents
  Other Cytotoxic Agents
  Other Types of Payloads
  Payload Not Disclosed or Specified

6. CORPORATE ANTIBODY-DRUG CONJUGATE R&D PIPELINES


More Publications